Clearpoint Neuro Net Income
| CLPT Stock | USD 13.46 0.89 7.08% |
As of the 9th of February, Clearpoint Neuro shows the risk adjusted performance of (0.06), and Mean Deviation of 3.6. Clearpoint Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Clearpoint Neuro Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 11.6082 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -17 M | -16.2 M | |
| Net Loss | -14.8 M | -14.1 M | |
| Net Loss | -17 M | -17.9 M | |
| Net Loss | (0.63) | (0.66) |
Clearpoint | Net Income | Build AI portfolio with Clearpoint Stock |
The evolution of Net Income for Clearpoint Neuro provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Clearpoint Neuro compares to historical norms and industry peers.
Latest Clearpoint Neuro's Net Income Growth Pattern
Below is the plot of the Net Income of Clearpoint Neuro over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Clearpoint Neuro financial statement analysis. It represents the amount of money remaining after all of Clearpoint Neuro operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Clearpoint Neuro's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearpoint Neuro's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (18.91 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Clearpoint Net Income Regression Statistics
| Arithmetic Mean | (10,723,401) | |
| Coefficient Of Variation | (51.30) | |
| Mean Deviation | 4,788,431 | |
| Median | (8,311,411) | |
| Standard Deviation | 5,500,765 | |
| Sample Variance | 30.3T | |
| Range | 17.6M | |
| R-Value | (0.74) | |
| Mean Square Error | 14.5T | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | (809,537) | |
| Total Sum of Squares | 484.1T |
Clearpoint Net Income History
Other Fundumenentals of Clearpoint Neuro
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Clearpoint Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Clearpoint Neuro is extremely important. It helps to project a fair market value of Clearpoint Stock properly, considering its historical fundamentals such as Net Income. Since Clearpoint Neuro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Clearpoint Neuro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Clearpoint Neuro's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Clearpoint introduce new products? Factors like these will boost the valuation of Clearpoint Neuro. Projected growth potential of Clearpoint fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Clearpoint Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 0.091 | Return On Assets | Return On Equity |
The market value of Clearpoint Neuro is measured differently than its book value, which is the value of Clearpoint that is recorded on the company's balance sheet. Investors also form their own opinion of Clearpoint Neuro's value that differs from its market value or its book value, called intrinsic value, which is Clearpoint Neuro's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Clearpoint Neuro's market value can be influenced by many factors that don't directly affect Clearpoint Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Clearpoint Neuro's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Clearpoint Neuro should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Clearpoint Neuro's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Clearpoint Neuro 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Clearpoint Neuro's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Clearpoint Neuro.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Clearpoint Neuro on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Clearpoint Neuro or generate 0.0% return on investment in Clearpoint Neuro over 90 days. Clearpoint Neuro is related to or competes with Si Bone, Avanos Medical, Varex Imaging, Orthofix Medical, Compass Pathways, Cytek Biosciences, and Standard Biotools. ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States More
Clearpoint Neuro Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Clearpoint Neuro's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Clearpoint Neuro upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 21.07 | |||
| Value At Risk | (7.79) | |||
| Potential Upside | 7.36 |
Clearpoint Neuro Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearpoint Neuro's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Clearpoint Neuro's standard deviation. In reality, there are many statistical measures that can use Clearpoint Neuro historical prices to predict the future Clearpoint Neuro's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.25) |
Clearpoint Neuro February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 3.6 | |||
| Coefficient Of Variation | (1,142) | |||
| Standard Deviation | 4.7 | |||
| Variance | 22.11 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 21.07 | |||
| Value At Risk | (7.79) | |||
| Potential Upside | 7.36 | |||
| Skewness | 0.0815 | |||
| Kurtosis | 0.416 |
Clearpoint Neuro Backtested Returns
Clearpoint Neuro secures Sharpe Ratio (or Efficiency) of -0.0776, which signifies that the company had a -0.0776 % return per unit of standard deviation over the last 3 months. Clearpoint Neuro exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Clearpoint Neuro's risk adjusted performance of (0.06), and Mean Deviation of 3.6 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Clearpoint Neuro will likely underperform. At this point, Clearpoint Neuro has a negative expected return of -0.33%. Please make sure to confirm Clearpoint Neuro's total risk alpha, as well as the relationship between the skewness and day median price , to decide if Clearpoint Neuro performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.01 |
Very weak reverse predictability
Clearpoint Neuro has very weak reverse predictability. Overlapping area represents the amount of predictability between Clearpoint Neuro time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Clearpoint Neuro price movement. The serial correlation of -0.01 indicates that just 1.0% of current Clearpoint Neuro price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.66 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Clearpoint Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Clearpoint Neuro reported net income of (18.91 Million). This is 105.54% lower than that of the Health Care Equipment & Supplies sector and 107.94% lower than that of the Health Care industry. The net income for all United States stocks is 103.31% higher than that of the company.
Clearpoint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearpoint Neuro's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics of similar companies.Clearpoint Neuro is currently under evaluation in net income category among its peers.
Clearpoint Neuro Current Valuation Drivers
We derive many important indicators used in calculating different scores of Clearpoint Neuro from analyzing Clearpoint Neuro's financial statements. These drivers represent accounts that assess Clearpoint Neuro's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Clearpoint Neuro's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 232.6M | 204.8M | 167.1M | 415.7M | 374.1M | 392.8M | |
| Enterprise Value | 190.8M | 189.2M | 157.9M | 399.1M | 359.2M | 377.2M |
Clearpoint Neuro ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Clearpoint Neuro's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Clearpoint Neuro's managers, analysts, and investors.Environmental | Governance | Social |
Clearpoint Neuro Institutional Holders
Institutional Holdings refers to the ownership stake in Clearpoint Neuro that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Clearpoint Neuro's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Clearpoint Neuro's value.| Shares | Cahill Wealth Management, Llc | 2025-03-31 | 245.3 K | Northern Trust Corp | 2025-06-30 | 204.8 K | Cm Management, Llc | 2025-06-30 | 200 K | Taylor Frigon Capital Management Llc | 2025-06-30 | 180.4 K | Conway Capital Management Inc | 2025-06-30 | 164.2 K | Ubs Group Ag | 2025-06-30 | 155.4 K | Parsons Capital Management Inc | 2025-06-30 | 143.5 K | Bank Of America Corp | 2025-06-30 | 113.7 K | Millennium Management Llc | 2025-06-30 | 99.9 K | Blackrock Inc | 2025-06-30 | 1.7 M | Vanguard Group Inc | 2025-06-30 | 1.5 M |
Clearpoint Fundamentals
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 398.53 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Shares Owned By Insiders | 7.80 % | ||||
| Shares Owned By Institutions | 41.96 % | ||||
| Number Of Shares Shorted | 3.18 M | ||||
| Price To Earning | (3.36) X | ||||
| Price To Book | 25.26 X | ||||
| Price To Sales | 11.66 X | ||||
| Revenue | 31.39 M | ||||
| Gross Profit | 21.05 M | ||||
| EBITDA | (17.84 M) | ||||
| Net Income | (18.91 M) | ||||
| Cash And Equivalents | 45.14 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 3.57 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 10.33 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (8.95 M) | ||||
| Short Ratio | 4.34 X | ||||
| Earnings Per Share | (0.83) X | ||||
| Price To Earnings To Growth | (0.46) X | ||||
| Target Price | 29.0 | ||||
| Number Of Employees | 115 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 400.41 M | ||||
| Total Asset | 39.19 M | ||||
| Retained Earnings | (191.37 M) | ||||
| Working Capital | 23.01 M | ||||
| Current Asset | 8.1 M | ||||
| Current Liabilities | 1.85 M | ||||
| Net Asset | 39.19 M |
About Clearpoint Neuro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.